文献速递外周动脉疾病

透析患者使用与不使用紫杉醇涂层器械治疗后的死亡率

Mortality Following Treatment With and Without Paclitaxel-Coated Devices in Dialysis Patients.
PubMed 文献 · J Endovasc Ther · 2022-09-01

该回顾性分析纳入2010至2018年359例接受髂动脉、股腘动脉和/或膝下病变治疗的透析患者,比较紫杉醇涂层器械与未涂层器械治疗后的死亡率。全体队列中未涂层组总死亡率为95.1%,紫杉醇组为75.9%(p<0.001);倾向评分匹配(n=119)后分别为95.0%和78.2%(p<0.001)。多因素分析显示年龄和严重肢体缺血是死亡的独立预测因素,紫杉醇治疗是死亡的保护因素。

要点

  • 透析患者总死亡率高,未涂层器械治疗后死亡率高于紫杉醇涂层器械。
  • 倾向评分匹配后未涂层组死亡率95.0%,紫杉醇组78.2%(p<0.001)。
  • 年龄和严重肢体缺血是死亡的独立预测因素,紫杉醇治疗为保护因素。

核心结论

  • 透析患者总体死亡率高,使用未涂层器械后的死亡率高于紫杉醇涂层器械。
  • 死亡的预测因素为危险因素和疾病严重程度,而非紫杉醇治疗。

研究设计与样本

  • 回顾性死亡率分析,纳入2010至2018年接受髂动脉、股腘动脉和/或膝下病变治疗的透析患者,共359例。
  • 未涂层器械组122例(随访期间未交叉至紫杉醇涂层器械),紫杉醇涂层器械组237例;平均随访27.38±24.76个月(范围0-103)。
  • 倾向评分匹配后样本量为n=119。

主要发现

  • 全体队列总死亡率:未涂层组95.1% vs 紫杉醇组75.9%(p<0.001)。
  • 倾向评分匹配后总死亡率:未涂层组95.0% vs 紫杉醇组78.2%(p<0.001)。
  • 全体队列多因素logistic回归分析显示年龄(p=0.002)和严重肢体缺血(p<0.001)为死亡的独立预测因素。
  • 紫杉醇治疗为死亡的保护因素(p<0.001)。

临床怎么用

  • 作者认为,在透析患者中,与未涂层器械相比,紫杉醇涂层器械治疗后生存更好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the mortality after treatment with a paclitaxel (PTX)-coated device and with uncoated devices of iliac, femoropopliteal, and below-the-knee lesions in dialysis patients. METHODS: Retrospective mortality analysis of dialysis patients with peripheral artery disease who underwent treatment of iliac, femoropopliteal, and/or infrapopliteal lesions with PTX-coated or uncoated devices. RESULTS: Between 2010 and 2018, 1125 dialysis patients were treated with iliac and/or femoropopliteal and/or infrapopliteal lesions. In all, 359 patients were selected for this retrospective analysis. Of those, 122 patients were treated with uncoated devices without crossover to a PTX-coated device during follow-up and 237 patients were treated with a PTX-coated device. Mean follow-up time was 27.38±24.76 months (range=0-103). For the entire cohort, the overall mortality was 95.1% after uncoated treatment and 75.9% after PTX treatment (p<0.001). After propensity score matching (n=119), overall mortality was 95.0% after uncoated treatment and 78.2% after PTX treatment (p<0.001). For the entire cohort, multivariate logistic regression analysis revealed age (p=0.002) and critical limb ischemia (p<0.001) as independent predictors for mortality. PTX treatment was a protective factor for mortality (p<0.001). CONCLUSION: Mortality in dialysis patients is in general high and higher after use of uncoated devices compared with PTX-coated devices. Mortality predictors were risk factors and disease severity but not PTX treatment. CLINICAL IMPACT: After the publication of Katsanos's metaanalyses, the uncertainty regarding PTX device safety in peripheral interventions in patients mainly without end-stage renal insufficiency was initially considerable. The present study for the first time investigates the potential long-term mortality risk of dialysis patients following PTX device treatment of PAD. In contrast to a recent meta-analysis, this real-world study could show a better survival after PTX treatment in comparison to uncoated devices.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Böhme T, Noory E, Beschorner U, et al. Mortality Following Treatment With and Without Paclitaxel-Coated Devices in Dialysis Patients. J Endovasc Ther. 2022. PMID: 36052426. doi:10.1177/15266028221120524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。